KLRK1 and neoplasm: For instance, in a Phase I single-arm trial (n = 12) involving patients with advanced colorectal cancer, infusion of CAR-NK cells targeting NKG2D ligands resulted in tumor shrinkage in some patients without the occurrence of serious adverse reactions [39].